Interventions for treating anxiety after stroke by Campbell Burton, C. Alexia et al.
Interventions for treating anxiety after stroke (Review)
Campbell Burton CA, Holmes J, Murray J, Gillespie D, Lightbody CE, Watkins CL, Knapp P
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2011, Issue 12
http://www.thecochranelibrary.com
Interventions for treating anxiety after stroke (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
10DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterventions for treating anxiety after stroke (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for treating anxiety after stroke
C. Alexia Campbell Burton1 , John Holmes2, Jenni Murray3, David Gillespie4, C. Elizabeth Lightbody5 , Caroline L Watkins5 , Peter
Knapp6
1School of Healthcare, University of Leeds, Leeds, UK. 2Academic Unit of Psychiatry, University of Leeds, Leeds, UK. 3Institute of
Health Sciences, University of Leeds, Leeds, UK. 4Department of Neuropsychology, Astley Ainslie Hospital, Edinburgh, UK. 5School
of Health, University of Central Lancashire, Preston, UK. 6Department of Health Sciences, University of York, York, UK
Contact address: C. Alexia Campbell Burton, School of Healthcare, University of Leeds, Baines Wing Room 3.35, Leeds, LS2 9JT,
UK. hccac@leeds.ac.uk.
Editorial group: Cochrane Stroke Group.
Publication status and date: New, published in Issue 12, 2011.
Review content assessed as up-to-date: 6 May 2011.
Citation: Campbell Burton CA, Holmes J, Murray J, Gillespie D, Lightbody CE, Watkins CL, Knapp P. Interven-
tions for treating anxiety after stroke. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD008860. DOI:
10.1002/14651858.CD008860.pub2.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Approximately 20% of stroke patients experience anxiety at some point after stroke.
Objectives
To determine if any treatment for anxiety after stroke decreases the proportion of patients with anxiety disorders or symptoms, and to
determine the effect of treatment on quality of life, disability, depression, social participation, risk of death or caregiver burden.
Search methods
We searched the trials register of the Cochrane Stroke Group (October 2010), CENTRAL (The Cochrane Library 2010, Issue 4), MED-
LINE (1950 to October 2010), EMBASE (1947 to October 2010), PsycINFO (1806 to October 2010), Allied and Complementary
Medicine database (AMED) (1985 to October 2010), Cumulative Index to Nursing and Allied Health (CINAHL) (1982 to October
2010), Proquest Digital Dissertations (1861 to October 2010), and Psychological Database for Brain Impairment Treatment Efficacy
(PsycBITE) (2004 to October 2010). In an effort to identify further published, unpublished and ongoing trials, we searched trial
registries and major international stroke conference proceedings, scanned reference lists, and contacted select individuals known to the
review team who are actively involved in psychological aspects of stroke research, and the Association of the British Pharmaceutical
Industry.
Selection criteria
Two review authors independently screened and selected titles and abstracts for inclusion in the review. Randomised trials of any
intervention in patients with stroke where the treatment of anxiety was an outcome were eligible.
Data collection and analysis
Two review authors independently extracted data for analysis. We performed a narrative review. A meta-analysis was planned but not
carried out as studies were not of sufficient quality to warrant doing so.
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Main results
We included two trials (three interventions) involving 175 participants with co-morbid anxiety and depression in the review. Both trials
used the Hamilton Anxiety Scale (HAM-A) to assess anxiety, and neither included a placebo control group. One trial randomised 81
patients to paroxetine, paroxetine plus psychotherapy or standard care. Mean level of anxiety severity scores were 58% and 71% lower
in the paroxetine, and paroxetine plus psychotherapy groups respectively compared with those in standard care at follow-up (P < 0.01).
The second trial randomised 94 stroke patients, also with co-morbid anxiety and depression, to receive buspirone hydrochloride or
standard care. At follow-up, themean level of anxiety was significantly lower for those receiving buspirone relative to controls (P < 0.01).
Half of the participants receiving paroxetine experienced adverse events that included nausea, vomiting or dizziness; however, only
14% of those receiving buspirone experienced nausea or palpitations. No information was provided about the duration of symptoms
associated with adverse events.
Authors’ conclusions
There is insufficient evidence to guide the treatment of anxiety after stroke. The data available suggest that pharmaceutical therapy
(paroxetine and buspirone) may be effective in reducing anxiety symptoms in stroke patients with co-morbid anxiety and depression.
No information was available for stroke patients with anxiety only. Randomised placebo controlled trials are needed.
P L A I N L A N G U A G E S U M M A R Y
Interventions for treating anxiety after stroke
Anxiety after stroke occurs frequently and can be treated with antidepressants, other anxiety reducing drugs, or psychological therapy.
This review of two trials, which included 175 participants, found that antidepressant and anxiety reducing drugs decreased the severity
of anxiety symptoms. However, they also increased side effects. One trial showed that combining an antidepressant with psychotherapy
also decreased anxiety symptom severity but not to a greater extent than antidepressant treatment alone. The findings are only applicable
to stroke patients with both anxiety and depression as we did not find any studies that considered stroke patients with anxiety only.
Future research will need to ensure that stroke patients with anxiety alone are also included in trials, and these trials should include a
placebo control group.
B A C K G R O U N D
Description of the condition
Stroke and anxiety disorders are both major public health prob-
lems. While stroke is the leading cause of adult disability
(Department ofHealth 2007), anxiety is themost commonmental
health disorder (Lepine 2002). Prevalence of anxiety after stroke
ranges between 20% to 25% (Burvill 1995; Lincoln 1998), and
it remains a common problem several years after the stroke event
(Sharpe 1990; Astrom 1996; Langhorne 2000).
There are several distinct types of anxiety disorders such as general
anxiety disorder (GAD), panic disorder, social phobia, obsessive
compulsive disorder (OCD), and post-traumatic stress disorder
(PTSD). While categorically different, they share similar hallmark
characteristics of excessive and irrational fear, subjective apprehen-
sion, and difficulty and distress in managing daily tasks (Gelder
2006). Furthermore, although diagnosed with an anxiety disor-
der, many individuals experience significant levels of physical (e.g.
heart palpitations, shortness of breath), cognitive (e.g. feeling of
losing control), or behavioural (e.g. avoidance of certain stimuli)
symptoms of anxiety that can affect their daily lives. All types of
anxiety disorders have been observed in stroke patients (House
1991; Max 2002), and have been shown to have a negative impact
on quality of life (Ahlsio 1984). Co-morbidity with depression is
also very high (Castillo 1993). Studies found that depression is
more severe and longer lasting in those with co-morbid anxiety
(Shimoda 1998), and stroke patients with co-morbid anxiety and
depression had higher levels of impairment in activities of daily
living, more cognitive impairment and fewer social ties than those
with depression alone (Shimoda 1998).
Differentiating between normal worries and the emergence of
pathological anxiety disorders, or clinically significant levels of anx-
iety symptoms, is difficult for several reasons. Being of advanced
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age or having limited verbal ability increases the difficulty in iden-
tifying persons suffering from anxiety (Van Rijswijk 2009), both of
which are common within the stroke population. Other practical
problems, such as difficulty in accessing specialist mental health
services, patients not presenting for treatment, and lack of clinical
guidelines specific to stroke patients with anxiety problems, mean
that individuals may go untreated.
Description of the intervention
We were interested in pharmaceutical, psychological, or any alter-
native therapy whose primary purpose was to treat anxiety disor-
ders or significant levels of anxiety symptoms in stroke patients.
Given the potential diversity of anxiety states, we did not limit
our criteria to an a priori list of therapies. We did, however, expect
to find studies that treated anxiety according to evidence-based
guidelines, such as those recommended by the National Institute
for Health and Clinical Excellence (NICE 2011), which outline
pharmaceutical and psychological interventions used to treat cer-
tain anxiety disorders in the general population. To our knowledge
no specific guidelines have been developed for the treatment of
anxiety in stroke patients.
Pharmaceutical therapies
Several classes of drugs can be used to treat anxiety disorders.
The drugs vary according to the neurotransmitters which they are
purported to affect.
Selective serotonin reuptake inhibitors (SSRIs) are a class of antide-
pressant drugs used to treat anxiety. Serotonin is a neurotransmit-
ter involved in regulating mood. SSRIs, such as fluoxetine, sertra-
line, escitalopram, paroxetine and citalopram, are commonly pre-
scribed for panic disorder,OCD, PTSDand social phobia (NIMH
2009). Pharmacologically, SSRIs inhibit the post-release reuptake
of serotonin by pre-synaptic nerve terminals, hence increasing the
level of available serotonin in the brain (Craig 2003).
Tricyclic antidepressants (TCAs) (e.g. imipramine) are an older
generation of antidepressant drug developed in the 1950s, and
have been replaced for the most part by SSRIs. They are, how-
ever, still recommended in clinical guidelines for treating GAD
and panic disorder (NICE 2011). TCAs act as serotonin and nore-
pinephrine reuptake inhibitors, which results in increasing the ex-
tracellular concentration of these neurotransmitters hence enhanc-
ing neurotransmission.
Benzodiazepines (e.g. diazepam and alprazolam) are anxiolytics
used to treat GAD and social phobia (Baldwin 2005), and in some
instances specific phobia (NICE 2011). These drugs enhance the
effect of the gamma-aminobutyric acid (GABA) neurotransmit-
ter which serves to reduce the somatic symptoms associated with
anxiety, such as muscle tension and insomnia but are only recom-
mended for short-term use.
Zopiclone, zaleplone, and zaleplon (Z-drugs), are hypnotics that
can be prescribed to assist for sleep disturbance seen in GAD
and PTSD (NICE 2005). These drugs behave in a similar way to
benzodiazepines except they have a shorter half-life.
Psychological therapies
Various forms of psychological therapies are available for treating
anxiety. They may be welcomed by individuals (especially older
people) who may prefer not to use psychotropic drugs (Givens
2006). This preference is based on concern about dependence,
prior negative experiences and the fact that many individuals do
not view their psychological symptoms as a medical illness (Givens
2006). Several forms of psychological therapies are described be-
low.
Behaviour therapy is based on learning theory, and patients are
shown approaches to develop adaptive ways of behaving. The aim
of behaviour therapy is to treat anxiety through techniques de-
signed to reinforce desired behaviours and eliminate undesired
ones.
Cognitive therapy is based on the cognitive model which hypoth-
esises that a person’s emotions and behaviours are influenced by
their perception of events. Hence it is not the situation itself that
determines how a person feels but rather the way in which they
construe the situation (Beck 1979).
Cognitive behaviour therapy (CBT) incorporates elements from
both cognitive and behaviour therapy. It seeks to change a person’s
thoughts, beliefs, attitudes, expectations and, as in behavioural
therapy, change how people act. It is ’present-centred’ and directs
the individual to identify the current issues that are causing them
distress, with the support of a trained psychological practitioner.
Individuals talk about the specific problems in a structured man-
ner with their therapist and may be given homework in the form
of activities to complete before their next session. CBT is charac-
terised as structured, goal-oriented and time-limited (Beck 1997).
Complementary or alternative therapies
While we cannot provide an exhaustive description of all inter-
ventions that could be used to treat anxiety there are a mix of
alternative therapies that patients may seek. For example self-help
manuals, with limited therapist involvement may assist patients in
gaining understanding or insight into their emotional problems,
can be used to treat anxiety disorders or severe symptoms (Van
Boeijen 2005). Other therapies such as exercise training, which
may act as a buffer for stress or trigger the release of monoamine
neurotransmitters, and relaxation therapy, which teaches individ-
uals to recognise the symptoms of anxiety and respond to them
with a technique that reduces arousal, have also been used to treat
anxiety (Jorm 2004).
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How the intervention might work
Pharamaceutical interventions work by altering the level of certain
neurotransmitters in the brain, while psychological interventions
aim to alter maladaptive behaviour and cognitions in order to
improve emotional functioning. There are multiple mechanisms
through which treatments in the complementary and alternative
category could work. Additionally, a placebo effect is also possible,
whereby participants receiving standard care, or those waiting to
receive an intervention, experience a reduction in anxiety symp-
toms that is not directly related to the action of the intervention
treatment.
Why it is important to do this review
Anxiety after stroke has received substantially less attention, both
clinically and in research, than other psychological outcomes. Sys-
tematic reviews have already been carried out to assess the effective-
ness of interventions used to treat depression and emotionalism
when they occur after stroke (Hackett 2008; Hackett 2010). Cur-
rently there are no equivalent published systematic reviews of inter-
ventions used to treat anxiety after stroke, thus highlighting a gap
in the literature and knowledge base. Studies in stroke (Shimoda
1998) and non-stroke populations (Wittchen 2003) have shown
that anxiety increases the risk and severity of depression. Hence,
early treatment of anxiety could reduce the risk of subsequent de-
pression and its associated adverse consequences. Clinical guide-
lines have been established for treating anxiety, but their effective-
ness in stroke populations remains unknown. We chose to evalu-
ate any intervention whose primary aim was to treat anxiety after
stroke as evidence suggests diversity among the preference of pa-
tients (Hyde 2005; Riedel-Heller 2005). However, we did expect
that the majority of the trials retrieved would be pharmaceutical
or psychologically-based interventions.
O B J E C T I V E S
1. The primary aim of this review was to assess the
effectiveness of pharmaceutical, psychological, complementary
or alternative therapy interventions in treating anxiety disorders
or symptoms in stroke patients.
2. The secondary aim was to identify whether any of these
interventions for anxiety had an effect on quality of life,
disability, depression, social participation, caregiver burden or
risk of death.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) where the primary aim of
the intervention was to treat anxiety in people with a clinical di-
agnosis of stroke (Hatano 1976) were eligible for inclusion in this
review. There was no restriction on the basis of language or study
location. We expected eligible trials to compare the effect of an
intervention plus usual care against placebo, a different interven-
tion, or different doses or frequency of interventions. Trials had to
have a placebo or standard care control arm otherwise they were
not eligible for inclusion.
Types of participants
All stroke patients enrolled into a RCT had to have either a clin-
ical diagnosis of an anxiety disorder according to the Diagnos-
tic and Statistical Manual of Mental Disorders (DSM-III (APA
1980), DSM-III-R (APA 1987), DSM-IV (APA 1994), DSM-IV-
TR (APA 2000)) or similar diagnostic criteria. Stroke patients in
RCTs deemed to have significant levels of anxiety symptoms as
established by a pre-determined researcher’s defined cut-off score
on an anxiety screening tool were also eligible. There were no re-
strictions on age distribution or gender. Studies with mixed pop-
ulations of Ischaemic or haemorrhagic stroke were eligible but
we excluded studies assessing treatment effect in an exclusively
subarachnoid haemorrhage patient population as the characteris-
tics, treatment, andmanagement of these patients are substantially
different to other stroke patients. Studies treating stroke patients
for other conditions such as depression, cognitive impairment or
physical disability were also ineligible, unless it could be deter-
mined that all patients had co-morbid anxiety upon enrolment
into the trial and treatment of the anxiety was one of the main
objectives of the trial.
Types of interventions
We evaluated RCTs of pharmaceutical interventions administered
to stroke patients compared with placebo or standard care. The
purpose of administering the drug had to be to treat anxiety. We
excluded trials where drugs were administered for other purposes,
such as neuro-protection.We includedpsychological interventions
compared with placebo or standard care, which aimed to treat
anxiety.We expected that these types of interventionswould have a
clearly defined psychological component, be structured, delivered
and supervised by trained staff, and be time-limited. We excluded
interventions whose purpose was simply to provide information
or educate patients. We did not include trials such as occupational
therapy or stroke support co-ordinator visitation unless they had
a definitive psychological component aimed at treating anxiety.
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Types of outcome measures
Primary outcomes
The primary outcomes of interest were:
1. the proportion of stroke patients without a clinical
diagnosis of an anxiety disorder according to the DSM (APA
1994) or another standard diagnostic classification at the end of
scheduled follow-up;
2. the proportion of stroke patients scoring outside the anxiety
symptom range (as defined by study author); or the change score
from baseline on an anxiety rating scale or via self-report at the
end of scheduled follow-up.
Secondary outcomes
1. Co-morbid depression, as diagnosed by DSM or
determined by a depression rating scale such as the Beck
Depression Inventory (BDI) (Beck 1961), the Hamilton
Depression scale (HAM-D) (Hamilton 1960) or the
Montgomery-Asberg Depression Rating Scale (Montgomery
1979).
2. Quality of life as measured on scales such as the 36-item
short form questionnaire (SF-36) (Ware 1993).
3. Social activities as measured on scales such as the Frenchay
Activities Index (Wade 1985).
4. Activities of daily living as measured on scales such as the
Barthel Index (Mahoney 1965).
5. Principal caregiver burden as measured by scales such as the
Zarit Caregiver Burden Interview (Zarit 1980).
6. Any adverse consequence as a result of treatment for anxiety
such as drug tolerance, co-dependence on counsellor or death.
We also recorded loss to follow-up rates in different arms of trials
as a possible indicator of treatment acceptability.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module.
Electronic searches
We searched the trials register of the Cochrane Stroke Group (last
searched October 2010). In addition, we also searched the follow-
ing bibliographic databases:
1. Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, 2010 Issue 4, searched
October 2010);
2. MEDLINE (1950 to October 2010) (Appendix 1);
3. EMBASE (1947 to October 2010) (Appendix 2);
4. PsycINFO (1806 to October 2010) (Appendix 3);
5. Allied and Complementary Medicine database (AMED)
(1985 to October 2010);
6. Cumulative Index to Nursing and Allied Health
(CINAHL) (1982 to October 2010);
7. Proquest Digital Dissertations which houses theses from
North American and select European universities (1861 to
October 2010).
Searching other resources
In an effort to identify further published, unpublished and ongo-
ing trials we:
1. searched the following ongoing trials registers:
ClinicalTrials.gov (http://www.clinicaltrials.gov/), Stroke Trials
Registry (www.strokecenter.org/trials/), Current Controlled
Trials (www.controlled-trials.com) (February 2011);
2. searched the conference proceedings from the UK Stroke
Forum (2006 to 2010), European Stroke Conference (2001 to
2010), and the International Stroke Conference (2007 to 2010)
not already searched by the Cochrane Stroke Group Trials Search
Co-ordinator;
3. searched PsycBITE (Psychological Database for Brain
Impairment Treatment Efficacy) (http://www.psycbite.com/),
accessed February 2011;
4. used Science Citation Index Cited Reference search for
forward tracking of relevant articles;
5. scanned the bibliographies of identified trials;
6. contacted experts known to our research group and
researchers with expertise in psychological disorder research,
identified by scanning authors of relevant publications;
7. contacted the Association of British Pharamaceutical
Industry, which includes the large majority of research-based
pharmaceutical companies, to request information about any
relevant unpublished trials. We did not receive any responses.
However, there is compulsory registration of trials on public
domain sites such as Clinicaltrials.gov and controlled-trials.com,
therefore, making it unlikely that additional trials would be
found.
We searched for relevant trials in all languages and arranged trans-
lation of trial reports published in languages other than English.
Data collection and analysis
Selection of studies
Two review authors (ACB and PK) independently screened all re-
ports yielded from the searches of electronic databases, and ex-
cluded citations that were clearly irrelevant based on title and ab-
stract. We retrieved the full text of the remaining articles and re-
viewed them for inclusion based on the eligibility criteria for the
review. If a consensus could not be reached, we had planned to
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consult a third review author (DG) for adjudication. However,
this was not necessary.
Data extraction and management
Two review authors (ACB and JM) independently extracted data
onto a paper extraction form where key information from stud-
ies was recorded. If information was missing, one review author
(ACB) attempted to contact the study authors, either by telephone
or email, to request the missing data. After the two authors rec-
onciled the data extraction, it was entered into Review Manager
5 (RevMan 2011). We recorded the following core data elements
such as study details, methods, information about participants and
outcomes for analysis.
Assessment of risk of bias in included studies
We assessed study bias in accordance with The Cochrane Collab-
oration’s tool for assessing risk of bias (Higgins 2008). This instru-
ment has six domains whereby different types of potential biases
can be evaluated. The domains are sequence generation, allocation
concealment, blinding (of participants, personnel and outcome
assessors), incomplete outcome data, selective outcome reporting
and other unspecified types of bias (e.g. conflict of interest). We
identified the respective biases from each study and displayed them
in a tabular format. We summarised the risks qualitatively and
attempted to describe their impact on the research findings.
Measures of treatment effect
Anarrative description of all studies was conducted. Both included
trials measured anxiety using the Hamilton Anxiety Scale (HAM-
A) (Hamilton 1959). The Hamilton Anxiety Scale is a rating scale
developed to quantify the severity of anxiety symptomatology, and
is often used in psychotropic drug evaluation. It consists of 14
items, each defined by a series of symptoms. Each item is rated on
a five-point scale, ranging from zero (not present) to four (severe).
Total scores on theHAM-A range from zero to 56. A score of 14 or
more has been suggested to indicate clinically significant anxiety.
Unit of analysis issues
In the event of outcomes being repeatedly observed in participants
(e.g. follow-up at four and six weeks), we reported the measure-
ment taken at the longest time point post intervention from each
study.
Dealing with missing data
We planned to contact study authors to obtain information about
missing data and, if unobtainable, conduct a ’what if ’ sensitivity
analysis exploring the impact the missing data could have on the
final outcome.
Assessment of heterogeneity
The intent was to measure heterogeneity with the I2 statistic. If
higher than 50% (a level considered to be a moderate to substan-
tial level), we would have reported the random-effects method
to measure treatment effect. The random-effects method assumes
that different studies are estimating different but related interven-
tion effects and so provides a more conservative intervention effect
estimate and wider confidence intervals (DerSimonian 1986).
Assessment of reporting biases
We planned to construct a funnel plot estimate to assess the po-
tential influence of reporting bias in the event of more than 10
studies being included in the systematic review.
Data synthesis
Two review authors (ACB and JM) independently extracted data
from included studies. One review author (ACB) entered data into
RevMan (RevMan 2011) and JM cross-checked the data entry.
The review authors resolved disagreements through reference to
the original study report.
Subgroup analysis and investigation of heterogeneity
Several factors could impact heterogeneity of studies and effect
size. We initially planned to undertake subgroup analyses on cer-
tain clinically relevant factors, such as specific type of anxiety dis-
order (e.g. GAD or social phobia), length of time treatment was
administered, or length of time since stroke at entry into the trial.
Sensitivity analysis
To test the robustness of findings and examine the degree to which
they influenced the effect size, we planned to analyse data and
include studies whereby allocation concealment, double blinding,
and fidelity to administered intervention were executed to the
highest standard.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We did not identify any trials that compared any intervention
with a placebo control. See: Characteristics of included studies;
Characteristics of excluded studies.
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Results of the search
The search yielded a total of 3486 unique titles (Figure 1). ACB
and PK carried out dual screening of all titles and abstracts and
retrieved 10 papers for full text review. Additionally, the search
yielded 13 systematic reviews that ACB reviewed for references.
However, no new references were found using this method. ACB
and JM conducted dual data extraction, and determined that two
studies met the inclusion criteria for this review,.
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Figure 1. Search flow diagram
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Included studies
Two trials with a total of 175 randomised participants met our
inclusion criteria (Wang 2005; Zhang 2005).
Wang 2005 evaluated the effectiveness of the selective serotonin
reuptake inhibitor (SSRI) paroxetine, and combination paroxe-
tine and psychotherapy. Eighty-one first-ever stroke patients who
met the Chinese Classification and Diagnostic Criteria of Mental
Disorders (CCMD-3) criteria were randomised to one of the three
groups. The first group (27 patients) received 20 mg of paroxetine
per day, while the second group (27 patients) received the same
amount of paroxetine per day along with psychiatrist administered
supportive psychotherapy for 30 to 60 minutes once per week. A
parallel control group with 27 patients received routine treatment
only. The study authors did not specify the length of time the
participants were post-stroke at time of recruitment. Patients who
were in a coma, aphasic, had severe cognitive dysfunction, other
serious diseases or those who had been prescribed depression or
antipsychotic medications in the three months prior to the onset
of the trial were excluded. The interventions were carried out for
six weeks and the HAM-A and the HAM-D scales were used to
assess the severity of anxiety and depression symptoms at baseline
and at the two, four and sixweek time points during the treatment.
Scores on the Barthel Index measuring activities of daily living
were also assessed at all time points. Mean ages of participants were
as follows: 62.4 years drug only group, 64.0 years in the drug plus
psychotherapy group, and 63.2 years in the standard care group.
Zhang 2005 examined the effect of the anxiolytic drug buspirone
hydrochloride against standard care. Ninety-four stroke patients
with co-morbid anxiety and depression according to theCCMD-3
were recruited into the trial. Individuals with unstable conditions
were deemed ineligible; however, no description of unstable con-
ditions was provided. Buspirone was administered for four weeks
to those in the intervention arm of the study. It was provided at 20
to 30 mg per dose during the first week, and then at 40 to 60 mg
per dose during the second week. No information was provided
about the amount administered during the third or fourth week.
Anxiety and depression were measured using the HAM-A and the
HAM-D scales at the baseline, and at two and four weeks during
the intervention. The mean age of participants was 57.8 years for
the intervention group, and 59.2 years for the control group. No
other secondary outcome of interest was reported.
Excluded studies
We excluded eight trials in total from the review. Three studies (Liu
2004; Ye 2006; Wu 2008) had no adequate control group (i.e. no
placebo or standard care only group). In four studies anxiety levels
of the participants were assessed but they did not necessarily meet
a pre-defined threshold definition so we could not establish that
all participants had anxiety upon entry into the study (Morrison
1998;Mok 2004; Li 2005; Rorsman 2006). In addition, Morrison
1998, Kimura 2003, and Li 2005 were not randomised control
trials. Morrison 1998 was a quasi experimental cohort study de-
sign using retrospective controls, and Li 2005 study participants
acted as their own controls. The criteria for entry into Kimura
2003 was depression and a subset analysis on cases with co-morbid
depression and GAD was conducted.
Risk of bias in included studies
Allocation
Wang et al stated they used simple random sampling, andZhang et
al indicated they used a random number list for participants who
met the inclusion criteria (Wang 2005;Zhang 2005).However, the
randomisation process was not described in either study, hence the
integrity of the sequence generation and allocation concealment
were unclear.
Blinding
Neither study provided information about blinding (Wang 2005;
Zhang 2005). As there was no placebo control group, blinding
would likely only be possible for independent outcome assessors.
Incomplete outcome data
One study (Wang 2005) recruited 81 participants with none lost
to follow-up. There was no indication that participants did not
adhere to treatment protocol in this study. The other study (Zhang
2005) reported outcomes for participants who remained until
completion of the study. Hence, it is classified as ’available case
analysis’.
Selective reporting
There was no evidence of selective outcome reporting in any of
the trials. All outcomes measured and reported in the methods
of these studies at the onset of the trial were reported at all time
points. However, we did not obtain the research protocols so we
do not know if other outcomes were measured but not reported.
Effects of interventions
In the absence of any placebo-control group and because of gen-
erally poor description of the study processes we did not perform
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a meta-analysis. The effectiveness of the interventions compared
with standard care are described.
Wang et al found that both paroxetine, and paroxetine plus psy-
chotherapy reduced the severity of anxiety symptoms as measured
by the HAM-A when compared with standard care (Wang 2005).
The mean HAM-A anxiety scores at baseline in the drug only,
drug plus psychotherapy, and standard care groups were 14.0 ±
(standard deviation (SD) = 2.8), 13.9 (SD = 2.9), and 13.8 (SD =
2.8) respectively. At six weeks themean anxiety scores were signifi-
cantly lower in the two intervention groups relative to the controls
5.4 (SD = 1.7), 3.8 (SD = 1.8) in the drug only, and drug plus
psychotherapy groups, but remained at 12.8 (SD = 1.9) in the
control group. Relative to the standard care group, this represents
a 58% and 71% lower mean anxiety score in the paroxetine, and
paroxetine plus psychotherapy groups respectively. These differ-
ences were statistically significant (P < 0.01). A similar trend was
observed for mean depression scores as measured by the HAM-
D. The possible range on the HAM-D is zero to 54, with higher
scores indicative ofmore severe symptoms.Mean depression sever-
ity scores were 18.2 (SD = 1.4), 18.8 (SD = 3.1), and 18.0 (SD =
1.3) at baseline in the paroxetine, paroxetine plus psychotherapy,
and standard care groups respectively. While no change was ob-
served in the control group after six weeks (mean 17.5, SD = 1.1),
both the drug only and drug plus psychotherapy groups had sig-
nificantly fewer depression symptoms (mean 10.1, SD = 1.1, and
mean 8.9, SD = 1.2), respectively. This was also the only trial that
reported changes in functional status as measured by the Barthel
Index of activities of daily living (ADL). They found that ADL im-
proved significantly in all three groups of patients but the greatest
improvement was observed in the drug plus psychotherapy group,
followed by the drug only group, with the standard care controls
having the least amount of improvement.
Zhang et al found that buspirone hydrocholoride was effective in
reducing anxiety symptoms when compared with standard care
(Zhang 2005). Four weeks after trial initiation the mean anxiety
score on the HAM-A decreased from 22.7 (SD = 5.2) to 6.5 (SD
= 3.1) in the intervention group. This was a significantly larger
decrease than seen in the standard care group (P < 0.01) where
the mean anxiety score decreased from 22.5 (SD = 4.3) to 12.6
(SD = 3.4) after four weeks. The mean in the intervention group
was 50% lower than those receiving standard care only. Buspirone
was also effective in significantly reducing depression symptoms
as measured on the HAM-D in the intervention group compared
with the controls. The mean depression score in the intervention
group decreased from 24.6 (SD = 4.7) to 8.3 (SD = 2.8) and from
23.4 (SD = 5.3) to 13.4 (SD = 2.7) in the standard care group.
The HAM-A scores range from zero to 54 with a score of more
than 17 indicative of mild tomoderate anxiety symptoms. On this
basis the reduction in anxiety scores in the intervention groups in
both trials appear to be meaningful. However, the authors did not
report their findings in terms of proportion no longer anxious so
the clinical significance of the effect is uncertain.
Adverse events and loss to follow-up
Noparticipants were lost to follow-up in theWang et al trial (Wang
2005). However, in both the intervention and control groups 23%
of participants were lost in the Zhang et al trial (Zhang 2005).
Reasons given for drop out in the intervention group were unsat-
isfactory treatment effect, drug side effects, and subsequent pre-
scription of benzodiazepines. Recurrent stroke, having benzodi-
azepines prescribed, and withdrawal were reasons given for loss to
follow-up in the control group.
Over 50% of participants receiving paroxetine in the Wang et al
study reported nausea or dizziness (Wang 2005), while 14% of
those receiving buspirone in the Zhang et al study reported either
nausea, dizziness or heart palpitations (Zhang 2005).
D I S C U S S I O N
Summary of main results
To our knowledge, this is the first systematic review of interven-
tions to treat anxiety after stroke. We found two published trials
and no ongoing trials. Of the two published trials, anxiety symp-
tom severity as measured by the Hamilton Anxiety Scale was the
outcome of interest. Neither study evaluated clinical anxiety dis-
orders or had a placebo control group. The results suggest that
both paroxetine and buspirone are effective therapies for treating
anxiety after stroke. However, in the absence of a placebo control
arm, the true level of effectiveness is uncertain. Combining parox-
etine and psychotherapy did not confer any significant additional
benefit for stroke patients. Paroxetine appears to be well tolerated
as there were no drop-outs among the patients but a large propor-
tion experienced symptoms of nausea or dizziness. Buspirone was
also effective in reducing anxiety, but there was substantial loss
to follow-up and some adverse events were reported. The loss to
follow-up in the buspirone trial is unusual as there was an equally
high level of drop out in the control group.
Overall completeness and applicability of
evidence
This review was deliberately broad as we suspected the literature
on interventions used to treat anxiety after stroke was not as es-
tablished as some of the other post-stroke psychological condi-
tions. We attempted to collate comprehensive evidence relevant
to the review question. Very little information was provided about
the populations from which the participants were selected, hence
the findings of this review may not even be generalisable to the
stroke population from which they were drawn let alone stroke
populations in other locales. Another concern was the inclusion
criteria for both studies required participants to have co-morbid
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anxiety and depression according to the CCMD-3. This would
result in stroke patients with only anxiety being deemed ineligible
for inclusion into the trial. As a result there is no evidence as to
whether any of the interventions described would be effective for
stroke patients who only had anxiety and not depression. It should
be noted that while the HAM-A is widely used in pharmaceutical
studies of anxiety it is not appropriate as a diagnostic or screen-
ing instrument. The HAM-A focuses primarily on the phobic and
autonomic arousal symptoms of anxiety, and gives little weight to
the psychic symptoms. Given the physical consequences of stroke,
it would be misleading to attribute all physical symptoms solely
to anxiety after stroke.
Quality of the evidence
Clear conclusions about the evidence cannot be drawn as many
of the quality indices were not adequately described, and study
sample size was small in both of the included trials. No study pro-
vided information on the length of time that had passed between
stroke and participant enrolment into the trial and no informa-
tion was provided about the setting from which participants were
recruited (e.g. hospital, or community based), which could influ-
ence prevalence of anxiety as hospital patients tend to have higher
levels of mood disturbance. Another issue is that neither study de-
scribed what was involved in the routine or standard care groups
which were used as the control comparison. Lastly, all studies inad-
equately reported their methodological indices such as allocation
concealment or blinding of participants and outcome assessors.
Potential biases in the review process
To the extent possible, there was minimal bias in the review pro-
cess. We undertook an extensive literature search guided by the
Cochrane Stroke Group, and contacted key researchers in the field
to obtain information about studies with a focus on post-stroke
anxiety. Additionally, we did not limit findings to English only pa-
pers. Two review authors independently decided whether studies
should be included and data were extracted independently by two
review authors.
Agreements and disagreements with other
studies or reviews
To our knowledge there are no other systematic reviews of inter-
ventions used to treat anxiety after stroke.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently there is insufficient evidence to guide practice in treat-
ing anxiety after stroke. The pharmaceutical therapies evaluated
indicate thatmedicationmay be an effective approach for reducing
anxiety symptoms in stroke patients with co-morbid anxiety and
depression when compared with standard care. The clinical signif-
icance of this decrease is unclear as the authors did not provide any
information about the proportion of study participants no longer
meeting the anxiety criteria. However, research has indicated that
a reduction of more than 50% on the Hamilton Anxiety Scale
is indicative of obvious improvement in the level of anxiety (Ye
2006).
Implications for research
Given the high prevalence of anxiety after stroke, placebo con-
trolled trials are needed to identify effective treatments for this
condition, as it can have a negative impact on other aspects of
life. Future research evaluating interventions to treat post-stroke
anxiety should assess outcomes such as quality of life and caregiver
burden as the trials in this review provided no information to de-
termine any impact of treatment on these outcomes. It will also
be useful for trials to investigate the effectiveness of psychological
interventions as none were found in this systematic review, and
for them to recruit patients with anxiety only as well as those with
co-morbid anxiety and depression.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Wang 2005
Methods RCT
Participants Location: China
81 CT/MRI confirmed first ever stroke according to CCMD-3 criteria with co-morbid
anxiety and depression
Group 1: 52% male, mean age 62.4 years (SD 6.1)
Group 2: 52% male, mean age 64.0 years (SD 5.3)
Group 3: 52% male, mean age 63.2 years (SD 5.7)
Interventions Intervention group 1: 27 participants, paroxetine 20 mg daily + routine treatment
Intervention group 2: 27 participants, paroxetine 20 mg daily + routine treatment +
psychiatrist administered individual supportive psychotherapy (30 to 60 minutes per
week)
Group 3: 27 participants, control group routine treatment only
Duration: 6 weeks
Outcomes Anxiety (HAM-A), depression (HAM-D), BI at 2, 4 and 6 weeks
Loss to follow-up: none
Adverse events: 26
1. Group 1: (14 total): minor nausea or stomach distension (9), dizziness (5)
2. Group 2: (12 total): minor nausea and vomiting (10), dizziness (2)
3. Group 3: none reported
Other outcomes: neurological impairment (SSS), activities of daily living (BI)
Notes Exclusions: coma, aphasia, severe cognitive dysfunction, other serious diseases, depression
or antipsychotic medications within 3 months, allergic to paroxetine, or bipolar disorder
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random number list (details not provided)
Allocation concealment (selection bias) Unclear risk Unknown
Blinding (performance bias and detection
bias)
Anxiety
Unclear risk Unknown
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not applicable; data available from all participants recruited to
study
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Wang 2005 (Continued)
Selective reporting (reporting bias) Low risk All outcomes measured at the onset of trial reported at all time
points
Other bias Unclear risk Unknown
Zhang 2005
Methods RCT
Participants Location: China
94 patients (47 each in control and intervention group) with clinical diagnosis of stroke
according to CCMD-3 criteria and affective disorders (72 included in final analysis)
Intervention group: 64% male, 57.8 years (SD 6.4)
Control group: 61% male, 59.2 years (SD 5.8)
Interventions Intervention group: 36 participants, buspirone hydrochloride 20 to 30 mg daily in first
week, 40 to 60 mg in second week + routine care
Control group: 36 participants, routine care (no description of routine care)
Duration: 4 weeks
Outcomes Anxiety (HAM-A) and depression (HAM-D) at 2 and 4 weeks
Loss to follow-up: 22 (11 in each group)
1. Intervention group: 7 withdrew before treatment, 1 unsatisfactory treatment
effects, 2 due to adverse effects, 1 prescribed benzodiazepines
2. Control group: 6 withdrew before treatment, 1 recurrent stroke, 4 prescribed
benzodiazepines
Adverese effects: 5
1. Intervention group: 3 dizziness and nausea, 2 palpitations
Other outcomes: American Heart Stroke Outcome Classification
Notes Exclusion: patients with unstable conditions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Anxiety
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
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Zhang 2005 (Continued)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk No information provided
BI: Barthel Index
CCMD-3: Chinese Classification of Mental Disorders Version 3
CT: computed tomography
HAM-A: Hamilton Anxiety Scale
HAM-D: Hamilton Depression Rating Scale
MRI: magnetic resonance imaging
RCT: randomised controlled trial
SD: standard deviation
SSS: Scandinavian Stroke Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kimura 2003 Design: cohort design
Allocation: unclear
Blinding: double blind
Participants: post-stroke with clinical diagnosis of moderate to severe depression. GAD only patients excluded.
This study carried out secondary analysis on a subset (27/106) participants who had co-morbid GAD
Intervention: daily nortriptyline 20 to 100 mg for 6 weeks. Dose escalated to 100 mg over duration of study;
placebo control
Li 2005 Design: self-controlled study
Allocation: not applicable
Blinding: unclear
Participants: post-stroke (all had anxiety levels measured, but did not necessarily meet any criteria to be defined as
anxious)
Interventions: early functional training which included component of supportive treatment without anti-anxiety
or antidepressant prescriptions. No placebo or standard care comparison
Liu 2004 Design: RCT
Allocation: number list, taking into account age, gender, and patient condition
Blinding: double blinded
Participants: post-stroke with anxiety (HAM-A ≥ 14)
Intervention: group 1 received 0.2 mg alprazolam every 8 hours + fluoxetine 20 mg once daily; group 2: alprazolam
every 8 hours. No placebo or standard care comparison
Mok 2004 Design: RCT
Allocation: random drawing of lots
Blinding: none, 1 researcher collected all data
17Interventions for treating anxiety after stroke (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Participants: post-stroke (anxiety assessed using Chinese State-Trait Anxiety Inventory, in all participants, but did
not necessarily meet criteria to be defined as anxious)
Intervention: slow stroke back massage
Morrison 1998 Design: quasi experimental cohort, with retrospective controls
Allocation: not applicable
Blinding: not applicable
Participants: post-stroke (level of anxiety assessed in all participants, but not necessarily meeting criteria for anxiety)
Intervention: self-help workbook aimed at enhancing non-avoidant coping and increasing personal control over
recovery
Rorsman 2006 Design: RCT
Allocation: yes, opaque randomised envelopes, numbered consecutively produced centrally by a computer
Blinding: yes, study co-ordinator and evaluators not granted to access on allocation
Participants: post-stroke only (all had anxiety levels measured, but did not necessarily meet any criteria to be defined
as anxious)
Interventions: group 1: electroacupuncture; group 2: transcutaneous electrical nerve stimulation
Wu 2008 Design: RCT
Allocation: process unclear
Blinding: not indicated
Participants: post-stroke anxiety neurosis (ICD-10)
Interventions: group 1 received alprazolam, group 2 received acupuncture. No placebo or standard care comparison
Ye 2006 Design: RCT
Allocation: unclear (not described)
Blinding: double blind (not described)
Participants: 90 stroke patients with co-morbid anxiety and depression defined as (> 14 on HAM-A and > 21 on
HAM-D)
Interventions: group 1 received paroxetine, group 2 received imipramine, control group received standard care and
rehabilitative training. No placebo or standard care only comparison
GAD: generalised anxiety disorder
HAM-A: Hamilton Anxiety Scale
HAM-D: Hamilton Depression Rating Scale
ICD: International Classification of Diseases
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. brain injuries/ or brain injury, chronic/
8. or/1-7
9. anxiety/
10. anxiety disorders/ or agoraphobia/ or obsessive-compulsive disorder/ or panic disorder/ or phobic disorders/ or exp stress disorders,
traumatic/
11. exp Anti-Anxiety Agents/
12. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?
traumatic stress$ or PTSD).tw.
13. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or terror)).tw.
14. manifest anxiety scale/
15. or/9-14
16. 8 and 15
17. Randomized Controlled Trials as Topic/
18. random allocation/
19. Controlled Clinical Trials as Topic/
20. control groups/
21. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
22. double-blind method/
23. single-blind method/
24. Placebos/
25. placebo effect/
26. cross-over studies/
27. Multicenter Studies as Topic/
28. Therapies, Investigational/
29. Drug Evaluation/
30. Research Design/
31. Program Evaluation/
32. evaluation studies as topic/
33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
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36. multicenter study.pt.
37. (evaluation studies or comparative study).pt.
38. random$.tw.
39. (controlled adj5 (trial$ or stud$)).tw.
40. (clinical$ adj5 trial$).tw.
41. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
42. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
43. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
44. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
45. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
46. (coin adj5 (flip or flipped or toss$)).tw.
47. (cross-over or cross over or crossover).tw.
48. placebo$.tw.
49. sham.tw.
50. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
51. controls.tw.
52. (treatment$ adj6 order).tw.
53. or/17-52
54. 16 and 53
55. limit 54 to humans
Appendix 2. EMBASE search strategy
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or
exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or cerebrovascular accident/ or exp intracranial aneurysm/
or exp occlusive cerebrovascular disease/ or stroke/ or stroke patient/ or stroke unit/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. paralysis/ or hemiparesis/ or hemiplegia/ or paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. brain injury/
8. or/1-7
9. anxiety/
10. exp anxiety disorder/
11. exp anxiolytic agent/
12. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?
traumatic stress$ or PTSD).tw.
13. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or terror)).tw.
14. beck anxiety inventory/ or hamilton anxiety scale/ or “hospital anxiety and depression scale”/ or self-rating anxiety scale/ or state
trait anxiety inventory/
15. or/9-14
16. Randomized Controlled Trial/
17. Randomization/
18. Controlled Study/
19. control group/
20. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical
trial/
21. Crossover Procedure/
22. Double Blind Procedure/
23. Single Blind Procedure/ or triple blind procedure/
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24. placebo/
25. Multicenter Study/
26. experimental design/ or experimental study/ or quasi experimental study/
27. experimental therapy/
28. drug comparison/ or drug dose comparison/
29. evaluation/ or “evaluation and follow-up”/ or evaluation research/ or clinical evaluation/
30. methodology/
31. “types of study”/
32. research subject/
33. Comparative Study/
34. random$.tw.
35. (controlled adj5 (trial$ or stud$)).tw.
36. (clinical$ adj5 trial$).tw.
37. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
38. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
39. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
40. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
41. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
42. (coin adj5 (flip or flipped or toss$)).tw.
43. (cross-over or cross over or crossover).tw.
44. placebo$.tw.
45. sham.tw.
46. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
47. controls.tw.
48. (treatment$ adj6 order).tw.
49. or/16-48
50. 8 and 15 and 49
51. limit 50 to human
Appendix 3. PsycINFO search strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. brain injur$.tw.
8. or/1-7
9. exp anxiety/
10. exp anxiety disorders/ or panic/ or panic attack/ or fear/
11. anxiety management/
12. state trait anxiety inventory/ or taylor manifest anxiety scale/
13. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?
traumatic stress$ or PTSD).tw.
14. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or terror)).tw.
15. or/9-14
16. 8 and 15
17. random sampling/
18. experiment controls/
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19. placebo/
20. (empirical study or treatment outcome clinical trial).md.
21. clinical trials/ or Treatment Effectiveness Evaluation/
22. random$.tw.
23. (controlled adj5 (trial$ or stud$)).tw.
24. (clinical$ adj5 trial$).tw.
25. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
26. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
27. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
28. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
29. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
30. (coin adj5 (flip or flipped or toss$)).tw.
31. (cross-over or cross over or crossover).tw.
32. placebo$.tw.
33. sham.tw.
34. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
35. controls.tw.
36. (treatment$ adj6 order).tw.
37. or/17-36
38. 16 and 37
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